Importantly, the fact that these pharmacological inhibitors for Atr and Chek1, which are already in clinical trials for cancer therapy, showed efficacy in promoting axon regeneration raises the possibility of repurposing these drugs for regeneration therapy. The gene discussed is CHEK1; the disease is cancer.